biphasic human insulin

Biphasic human insulin is a premixed suspension containing both rapid-acting soluble human insulin and intermediate-acting isophane (NPH) human insulin. This formulation is designed to provide a dual-action profile that mimics the physiological insulin response to meals while maintaining basal insulin levels. The soluble component acts quickly to control postprandial blood glucose, while the isophane component provides a prolonged effect to maintain glycemic control between meals and overnight. It is primarily indicated for the management of type 1 and type 2 diabetes mellitus. Major developers and manufacturers include Novo Nordisk, Eli Lilly, and Sanofi. It is typically administered via subcutaneous injection.

Brand names

MixtardHumulin 70/30Novolin 70/30Insuman Comb

Other names

biphasic isophane insulinpremixed human insulinhuman insulin 30/70